PharmTech Drug Digest 11.20
News|Articles|December 12, 2013

AstraZeneca Awarded Damages in Patent-Litigation

Author(s)Melanie Sena

AstraZeneca will receive $76 million in damages from Apotex Corp., Apotex, and Torpharm.

AstraZeneca reported a ruling by the US District Court for the Southern District of New York that ordered Apotex Corp., Apotex, and Torpharm, to pay AstraZeneca approximately $76 million in damages. This ruling is a result of Apotex’s infringing sales of generic omeprazole between 2004 and 2007. This follows a previous ruling in 2007 that found two Prilosec (omeprazole) formulation patents valid and infringed by Apotex.

Source: AstraZeneca


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.